Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVOID Neutropenia
2013-001284-23Phase 3Completed
- Sponsor
- Merckle GmbH
- Start
- Jul 2013
- Modality
- Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes, Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-Hodgkin lymphoma (NHL) comparing Lonquex arm with Neulasta arm (2 arms). Primary endpoint: Duration of severe neutropenia in cycle 1. Started Jul 2013; status: completed.
02
Drugs
lipegfilgrastimpegfilgrastim
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2013-001284-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001284-23.